Last reviewed · How we verify

Cygro — Competitive Intelligence Brief

Cygro (MADURAMICIN) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Other.

marketed 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B Other Small molecule Live · refreshed every 30 min

Target snapshot

Cygro (MADURAMICIN). Cygro works by binding to the 5-hydroxytryptamine receptor 6, a subtype of serotonin receptor.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Cygro TARGET MADURAMICIN marketed 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B
Cogentin Cogentin University of Southern California marketed 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B
Thenylene METHAPYRILENE marketed 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cygro — Competitive Intelligence Brief. https://druglandscape.com/ci/maduramicin. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: